| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/08/2011 | CA2480940C Non-steroidal progesterone receptor modulators |
| 02/08/2011 | CA2479906C Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors |
| 02/08/2011 | CA2478068C Dihydropyrazole compounds useful for treating or preventing cancer |
| 02/08/2011 | CA2471755C Process for preparing scopine esters |
| 02/08/2011 | CA2467064C Lipid carrier compositions with enhanced blood stability |
| 02/08/2011 | CA2464214C Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them |
| 02/08/2011 | CA2456604C Pharmaceutical composition comprising lumiracoxib |
| 02/08/2011 | CA2455766C Bioabsorbable adhesive compounds and compositions |
| 02/08/2011 | CA2446924C 2-iminopyrrolidine derivatives |
| 02/08/2011 | CA2442319C Carboxylic acid derivative and salt thereof |
| 02/08/2011 | CA2439117C Polymorph forms of n-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2-oxopyrrolidin-1-yl)acetamide |
| 02/08/2011 | CA2431461C 1,5 benzothiazepines and their use as antihyperlipidemics |
| 02/08/2011 | CA2419822C Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization |
| 02/08/2011 | CA2409854C Sustained release pharmaceutical compositions for the parenteral administration of biologically active hydrophilic compounds |
| 02/08/2011 | CA2409660C Novel process |
| 02/08/2011 | CA2403900C Substituted chalcones as therapeutic compounds |
| 02/08/2011 | CA2403475C Device and method for treating urinary incontinence in females |
| 02/08/2011 | CA2401424C Alprazolam inclusion complexes and pharmaceutical compositions thereof |
| 02/08/2011 | CA2370466C Methods of treatment using anti-erbb antibody-maytansinoid conjugates |
| 02/08/2011 | CA2369588C Anticancer calcium channel blockers |
| 02/08/2011 | CA2355717C 1,2-annelated quinoline derivatives |
| 02/08/2011 | CA2350433C Breath freshening comestible product |
| 02/08/2011 | CA2341574C Phosphohalohydrins, method for making same and uses |
| 02/08/2011 | CA2275525C Gel composition and methods |
| 02/08/2011 | CA2273353C Galenic composition containing opioid antagonists |
| 02/08/2011 | CA2271390C Method of enhancing the antimicrobial properties of antibacterial antibiotics |
| 02/08/2011 | CA2259603C Use of polymeric compositions for reducing or eliminating post-surgical adhesion formation |
| 02/08/2011 | CA2223407C Oxidant scavengers |
| 02/08/2011 | CA2220830C Novel human cyclin-dependent kinase-like proteins and methods of using the same |
| 02/08/2011 | CA2217967C Augmentation in serca2 mediated calcium ion transport for regulation of cardiac muscle contractility |
| 02/08/2011 | CA2210467C Osteoprotegerin |
| 02/04/2011 | CA2710224A1 Novel dihydroindolone derivatives, method for production thereof and pharmaceutical compositions comprising said derivatives |
| 02/03/2011 | WO2011014888A1 Novel hedgehog inhibitors |
| 02/03/2011 | WO2011014883A2 Skin rejuvenation and wrinkle treatment by gingival fibroblast and its growth factor: activation of effect by hyluronic acid |
| 02/03/2011 | WO2011014882A1 CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS |
| 02/03/2011 | WO2011014880A1 Inhibitors of cognitive decline |
| 02/03/2011 | WO2011014872A2 Compositions and methods for diagnosing, treating or preventing neoplasias |
| 02/03/2011 | WO2011014825A2 Antiangiogenic small molecules and methods of use |
| 02/03/2011 | WO2011014817A1 Pyrrolo [1, 2-b] pyridazine derivatives as janus kinase inhibitors |
| 02/03/2011 | WO2011014816A1 Wd repeat 79 protein targeted therapy |
| 02/03/2011 | WO2011014809A1 Hydrogel formulation comprising oxidative reductive potential water |
| 02/03/2011 | WO2011014794A1 Adenoviral-based vectors |
| 02/03/2011 | WO2011014793A2 Process for preparing fondaparinux sodium and intermediates useful in the synthesis thereof |
| 02/03/2011 | WO2011014781A1 Novel oral forms of a phosphonic acid derivative |
| 02/03/2011 | WO2011014776A1 Nitroimidazooxazine and nitroimidazooxazole analogues and their uses |
| 02/03/2011 | WO2011014775A1 Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses |
| 02/03/2011 | WO2011014774A1 Nitroimidazooxazines and their uses in anti-tubercular therapy |
| 02/03/2011 | WO2011014766A2 Crystallization method and bioavailability |
| 02/03/2011 | WO2011014726A1 Mtor inhibitor and angiogenesis inhibitor combination therapy |
| 02/03/2011 | WO2011014695A1 New 2,3,4,5-tetrahydro-1h-pyrido[4,3-b] indoles and methods of use |
| 02/03/2011 | WO2011014681A1 Poly (ADP-Ribose) Polymerase (PARP) INHIBITORS |
| 02/03/2011 | WO2011014679A1 Method and kit for treating nicotine addiction |
| 02/03/2011 | WO2011014661A2 Liver x receptor agonists |
| 02/03/2011 | WO2011014649A1 Compositions and methods for inhibiting hair growth |
| 02/03/2011 | WO2011014627A1 Combination of dapsone with adapalene |
| 02/03/2011 | WO2011014613A2 Preparation of fipamezole |
| 02/03/2011 | WO2011014611A2 Preparation of olmesartan medoxomil |
| 02/03/2011 | WO2011014600A1 Methods of treating neuropathic pain with benzimidazole derivative agonists of ppargamma |
| 02/03/2011 | WO2011014588A2 Dermal formulations of dp2 receptor antagonists |
| 02/03/2011 | WO2011014587A2 Ophthalmic pharmaceutical compositions of dp2 receptor antagonists |
| 02/03/2011 | WO2011014541A1 Stable formulations of azacitidine |
| 02/03/2011 | WO2011014535A1 COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION |
| 02/03/2011 | WO2011014516A1 Estrogen antagonists as treatments for sclerosing disorders |
| 02/03/2011 | WO2011014515A1 2, 7 -naphthyridin- 1 -one derivatives as syk kinase inhibitors |
| 02/03/2011 | WO2011014475A2 Treating negative symptoms of schizophrenia associated with defective neuregulin 1 |
| 02/03/2011 | WO2011014462A1 Fused heterocyclic compounds as ion channel modulators |
| 02/03/2011 | WO2011014457A1 Combination treatments |
| 02/03/2011 | WO2011014418A1 Vaccine stabilizer |
| 02/03/2011 | WO2011014332A1 Selective alpha 2b/2c agonists |
| 02/03/2011 | WO2011014299A2 Identification and use of small molecules to modulate transcription factor function and to treat transcription factor associated diseases |
| 02/03/2011 | WO2011014261A1 Fatty acids as anti-inflammatory agents |
| 02/03/2011 | WO2011014257A1 Approaches to treat cancer using hb-egf inhibitors such as myrsinoic acid a |
| 02/03/2011 | WO2011014255A1 Treatment of crohn's disease with laquinimod |
| 02/03/2011 | WO2011014248A1 Pharmaceutical compositions for the treatment of cancer and other diseases or disorders |
| 02/03/2011 | WO2011014247A1 Method to increase oxygen in male and female sexual organs through the topical use of perfluorocarbons |
| 02/03/2011 | WO2011014239A1 Anti-proliferative substituted pyrazolo[3,4-d]pyrimidines derivatives (spp) to inhibit immune activation, virus replication and tumor growth |
| 02/03/2011 | WO2011014208A1 Treating critically ill patients with intravenous ibuprofen |
| 02/03/2011 | WO2011014128A1 Small molecule inhibitors of isoprenylcysteine carboxyl methyltransferase with potential anticancer activity |
| 02/03/2011 | WO2011014122A1 System and method for extracting vitamin e from fatty acid distillates |
| 02/03/2011 | WO2011014098A1 Hydrogenated pyrido[4,3-b]indole derivatives, pharmaceutical composition and methods for the production and use thereof |
| 02/03/2011 | WO2011014084A1 Use of 5h-dibenz / b, f/ azepine-5-carboxamide derivatives for treating fibromyalgia |
| 02/03/2011 | WO2011014009A2 Novel di-substituted phenoxyacetyl-based compound or pharmaceutically acceptable salt thereof, production method for same and pharmaceutical composition for suppressing multiple drug resistance comprising same as an active ingredient |
| 02/03/2011 | WO2011014008A2 Novel 3-phenoxy-4-pyrone, 3-phenoxy-4-pyridone, or 4-pyridone derivatives, method for preparing same, and antimicrobial composition containing same as an active ingredient |
| 02/03/2011 | WO2011014003A2 (+)-3-hydroxymorphinan derivatives as neuroprotectants |
| 02/03/2011 | WO2011013999A2 Composition containing chitooligosaccharide for recovering from fatigue |
| 02/03/2011 | WO2011013992A2 R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and l-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial |
| 02/03/2011 | WO2011013987A2 2,2-disubstituted-2h-chromene compound |
| 02/03/2011 | WO2011013912A2 Pharmaceutical composition for enhancing radiation therapy for cancer, and method for screening active material for enhancing radiation therapy for cancer |
| 02/03/2011 | WO2011013909A2 Composition containing oligo-hyaluronic acid for promoting the stemness of skin cells and for stimulating differentiation |
| 02/03/2011 | WO2011013825A1 Antibacterial agent |
| 02/03/2011 | WO2011013794A1 Water-based composition for eye drop |
| 02/03/2011 | WO2011013785A1 Nitrogen-containing spiro-ring compound and medicinal use of same |
| 02/03/2011 | WO2011013752A1 Pharmaceutical composition containing fused hetero-ring derivative |
| 02/03/2011 | WO2011013735A1 Novel flavanone derivative |
| 02/03/2011 | WO2011013729A1 Fused imidazole derivative having ttk inhibitory action |
| 02/03/2011 | WO2011013699A1 Carrier peptide fragment and use thereof |
| 02/03/2011 | WO2011013668A1 Pharmaceutical composition for treatment of ischemic events |
| 02/03/2011 | WO2011013656A1 Pyrrolo[2,3-d]pyrimidine derivative |
| 02/03/2011 | WO2011013651A1 Bicyclic compound and use thereof for medical purposes |
| 02/03/2011 | WO2011013646A1 Pharmaceutical product for prevention and treatment of amyotrophic lateral sclerosis |